

Stephen R Durham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10605638/publications.pdf>

Version: 2024-02-01

88
papers

16,059
citations

31976
53
h-index

54911
84
g-index

88
all docs

88
docs citations

88
times ranked

8332
citing authors

#	ARTICLE	IF	CITATIONS
1	Predominant T _{H2} -like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma. <i>New England Journal of Medicine</i> , 1992, 326, 298-304.	27.0	2,719
2	Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy. <i>New England Journal of Medicine</i> , 1999, 341, 468-475.	27.0	1,256
3	Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. <i>Journal of Clinical Investigation</i> , 2009, 119, 3573-85.	8.2	840
4	Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. <i>Nature Medicine</i> , 1995, 1, 39-46.	30.7	736
5	Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity. <i>Journal of Immunology</i> , 2004, 172, 3252-3259.	0.8	496
6	Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 1255-1261.	2.9	486
7	Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 802-809.	2.9	470
8	Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 434-440.	2.9	415
9	Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon- β . <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 1356-1365.	2.9	383
10	Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 468-475.e6.	2.9	375
11	Mechanisms of immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 1025-1034.	2.9	372
12	Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 319-325.	2.9	353
13	Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1485-1498.	2.9	323
14	Immunologic changes associated with allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 157-164.	2.9	321
15	Sublingual Immunotherapy: World Allergy Organization Position Paper 2009. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1-59.	5.7	316
16	Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 131-138.e7.	2.9	311
17	Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 509-516.e5.	2.9	299
18	Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 1120-1125.e2.	2.9	289

#	ARTICLE	IF	CITATIONS
19	Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 915-922.	2.9	266
20	Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 87-93.	2.9	261
21	Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 881-891.	2.9	251
22	Tregs and allergic disease. <i>Journal of Clinical Investigation</i> , 2004, 114, 1389-1397.	8.2	235
23	IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1249-1256.	2.9	207
24	Asthma phenotypes and IgE responses. <i>European Respiratory Journal</i> , 2016, 47, 304-319.	6.7	197
25	Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 512-518.e2.	2.9	192
26	Sublingual or subcutaneous immunotherapy for allergic rhinitis?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 339-349.e10.	2.9	169
27	Allergen Immunotherapy in Children User's Guide. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 1-101.	2.6	169
28	Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to registration and beyond. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 30-38.	2.9	168
29	Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 615.	7.4	166
30	Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. <i>Immunity</i> , 2021, 54, 291-307.e7.	14.3	134
31	Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. <i>Immunology</i> , 2002, 105, 56-62.	4.4	132
32	Tregs and allergic disease. <i>Journal of Clinical Investigation</i> , 2004, 114, 1389-1397.	8.2	131
33	Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 688-695.	2.9	122
34	Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 971-976.	2.9	115
35	Specific immunotherapy modifies allergen-specific CD4+ T-cell responses in an epitope-dependent manner. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 872-879.e7.	2.9	110
36	Basophil expression of diamine oxidase: A novel biomarker of allergen immunotherapy response. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 913-921.e9.	2.9	101

#	ARTICLE	IF	CITATIONS
37	Sub-Lingual Immunotherapy. World Allergy Organization Journal, 2009, 2, 233-281.	3.5	100
38	IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy. Journal of Allergy and Clinical Immunology, 2005, 116, 73-79.	2.9	99
39	EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clinical and Translational Allergy, 2012, 2, 20.	3.2	97
40	Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy. Journal of Allergy and Clinical Immunology, 2019, 143, 1067-1076.	2.9	90
41	Allergen Immunotherapy and Tolerance. Allergology International, 2013, 62, 403-413.	3.3	88
42	The CX3C chemokine fractalkine in allergic asthma and rhinitis. Journal of Allergy and Clinical Immunology, 2003, 112, 1139-1146.	2.9	82
43	IL-22 suppresses IFN- γ -mediated lung inflammation in asthmatic patients. Journal of Allergy and Clinical Immunology, 2013, 131, 562-570.	2.9	79
44	Long-term clinical and immunological effects of allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 586-593.	2.3	76
45	Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opinion on Biological Therapy, 2013, 13, 1543-1556.	3.1	68
46	Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy. Frontiers in Immunology, 2020, 11, 599083.	4.8	68
47	Applications and mechanisms of immunotherapy in allergic rhinitis and asthma. Therapeutic Advances in Respiratory Disease, 2017, 11, 73-86.	2.6	67
48	Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. Journal of Allergy and Clinical Immunology, 2016, 138, 1081-1088.e4.	2.9	64
49	Synchronous immune alterations mirror clinical response during allergen immunotherapy. Journal of Allergy and Clinical Immunology, 2018, 141, 1750-1760.e1.	2.9	61
50	Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis. Current Treatment Options in Allergy, 2018, 5, 275-290.	2.2	58
51	Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Current Opinion in Allergy and Clinical Immunology, 2004, 4, 543-548.	2.3	57
52	One hundred years of allergen immunotherapy: Time to ring the changes. Journal of Allergy and Clinical Immunology, 2011, 127, 3-7.	2.9	57
53	A Nonallergenic Birch Pollen Allergy Vaccine Consisting of Hepatitis PreS α -Fused Bet v 1 Peptides Focuses Blocking IgG toward IgE Epitopes and Shifts Immune Responses to a Tolerogenic and Th1 Phenotype. Journal of Immunology, 2013, 190, 3068-3078.	0.8	57
54	Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: A double-blind, randomised study. Quality of Life Research, 2007, 16, 191-201.	3.1	55

#	ARTICLE	IF	CITATIONS
55	New approaches to allergen immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 293-305.	1.0	54
56	Immunological Responses and Biomarkers for Allergen-Specific Immunotherapy Against Inhaled Allergens. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1769-1778.	3.8	52
57	Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 106, 293-301.	2.9	49
58	Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 452-461.e9.	2.9	48
59	Sublingual immunotherapy: what have we learnt from the "big trials"? <i>Current Opinion in Allergy and Clinical Immunology</i> , 2008, 8, 577-584.	2.3	42
60	The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA2LEN) article. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 49-56.e11.	2.9	42
61	Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1061-1071.e11.	2.9	41
62	One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 454-468.	5.7	39
63	Allergen immunotherapy for allergic respiratory diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1499-1512.	3.3	38
64	Serum Immunologic Markers for Monitoring Allergen-Specific Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 311-323.	1.9	37
65	T lymphocytes in asthma: Bronchial versus peripheral responses. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 106, S221-S226.	2.9	36
66	Intradermal grass pollen immunotherapy increases T H 2 and IgE responses and worsens respiratory allergic symptoms. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1830-1839.e13.	2.9	35
67	Immunologic mechanisms of a short-course of Lolium perenne peptide immunotherapy: A randomized, double-blind, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 738-749.	2.9	35
68	Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 663-676.	2.9	34
69	Duration of allergen immunotherapy for inhalant allergy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 594-605.	2.3	32
70	Localization and up-regulation of Mucin (MUC2) gene expression in human nasal biopsies of patients with cystic fibrosis. <i>Journal of Pathology</i> , 1997, 181, 305-310.	4.5	30
71	Mechanisms of Sublingual Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 191-209.	1.9	26
72	CXCR1+CD4+T Cells in Human Allergic Disease. <i>Journal of Immunology</i> , 2004, 172, 268-273.	0.8	24

#	ARTICLE	IF	CITATIONS
73	NHS allergy services in the UK: proposals to improve allergy care. <i>Clinical Medicine</i> , 2002, 2, 122-127.	1.9	21
74	Allergen immunotherapy for long-term tolerance and prevention. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 802-811.	2.9	21
75	T Cell Phenotypes of the Normal Nasal Mucosa: Induction of Th2 Cytokines and CCR3 Expression by IL-4. <i>Journal of Immunology</i> , 2001, 166, 2303-2310.	0.8	17
76	Allergen immunotherapy (desensitisation) for allergic diseases. <i>Clinical Medicine</i> , 2006, 6, 348-351.	1.9	15
77	Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy. <i>Allergy and Asthma Proceedings</i> , 2022, 43, 292-298.	2.2	14
78	Allergen Immunotherapy: A Centenary Celebration. <i>World Allergy Organization Journal</i> , 2011, 4, 104-106.	3.5	13
79	Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. <i>Thorax</i> , 2014, 69, 335-345.	5.6	13
80	Immunomodulatory Treatment Strategies for Allergic Diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2003, 2, 31-46.	3.1	10
81	Tradition and innovation: Finding the right balance. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 792-795.	2.9	8
82	Allergic and Non-Allergic Rhinitis. , 2009, , 973-990.		8
83	Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). <i>Clinical and Translational Allergy</i> , 2013, 3, 27.	3.2	6
84	UK Immunotherapy Study: Reanalysis by a combined symptom and medication score. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1998-1999.e3.	2.9	6
85	Allergen Immunotherapy for a Teenager with Seasonal Allergic Rhinitis Due to Grass Pollen: Subcutaneous or Sublingual Route?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 52-57.	3.8	4
86	Allergen Immunotherapy. , 2001, 31, 186-190.		0
87	Immunotherapy for Allergy. , 2022, , 491-502.		0
88	Treatment of seasonal allergic rhinitis: Desensitisation for hay fever works. <i>BMJ: British Medical Journal</i> , 2003, 327, 1229-1229.	2.3	0